Up to 40% of dementia cases could be thwarted by modifying 12 key risk factors, according to a report by the Lancet Commission. Many of these factors can be tackled late in life, the authors say.
The experimental blood test rivals the accuracy of standard diagnostic methods and may soon prove to be a cost-effective, accessible tool in the clinical setting, according to some in the scientific community.
Increased physical activity provides greater protection against cognitive decline and brain tissue loss. A moderate walking routine can help.
Many residents with dementia also exhibit apathy. When overlooked in care settings, the consequences can be grave.
A path to quicker and easier diagnosis seems near. Blood tests have the potential to replace costly and intrusive diagnostics.
A lifetime of cognitively challenging activity is tied to lower dementia risk, even in people whose brains show signs of Alzheimer’s disease.
The odds of developing Alzheimer’s disease fell sharply among seniors in the United States over the last 30 years, according to research presented Tuesday at the Alzheimer’s Association International Conference in Copenhagen.
Avanir Pharmaceuticals has announced data on pseudobulbar affect, a neurological condition characterized by disruptive, uncontrollable episodes of laughing or crying, and NUEDEXTA®, the only FDA-approved product for the treatment of PBA. Results will be presented at the Alzheimer’s Association International Conference in Copenhagen, Denmark, which runs July 12 through 17.
The tendency of Alzheimer’s patients to wander at night could be tied to the quantity of daylight they’re exposed to, new research finds. As a result, experts say that “light therapy” could be helpful in treating this behavior.
Treatment with an experimental intravenous Alzheimer’s medication stabilized dementia symptoms for a sustained period in trial participants, new research reveals. Investigators called it a “first” in Alzheimer’s research.
